David Hoang
Stock Analyst at Deutsche Bank
(4.71)
# 697
Out of 4,355 analysts
110
Total ratings
66.2%
Success rate
28.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNLI Denali Therapeutics | Maintained: Buy | $35 → $31 | $21.04 | +47.34% | 9 | May 22, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $88 → $102 | $73.50 | +38.78% | 3 | May 12, 2026 | |
| PRAX Praxis Precision Medicines | Maintained: Buy | $437 → $420 | $349.97 | +20.01% | 8 | May 8, 2026 | |
| NBIX Neurocrine Biosciences | Maintained: Hold | $140 → $155 | $158.30 | -2.08% | 10 | May 7, 2026 | |
| AXSM Axsome Therapeutics | Rated: Buy | $281 → $280 | $234.48 | +19.41% | 9 | May 5, 2026 | |
| APGE Apogee Therapeutics | Reiterated: Buy | $118 | $82.14 | +43.66% | 3 | Apr 2, 2026 | |
| SRPT Sarepta Therapeutics | Maintained: Sell | $12 → $14 | $17.87 | -21.66% | 23 | Mar 26, 2026 | |
| ATAI AtaiBeckley | Initiated Coverage: Buy | $12 | $4.53 | +164.90% | 1 | Mar 26, 2026 | |
| XENE Xenon Pharmaceuticals | Maintained: Buy | $60 → $90 | $54.73 | +64.44% | 9 | Mar 10, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintained: Buy | $255 → $226 | $236.49 | -4.44% | 5 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $36 → $30 | $31.59 | -5.03% | 6 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52 → $45 | $42.19 | +6.66% | 3 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $29 | $21.66 | +33.89% | 9 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $65 | $11.01 | n/a | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $7 | $2.60 | n/a | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $7.34 | n/a | 3 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $3.87 | n/a | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $220 | $301.98 | n/a | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $80 | $77.91 | n/a | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $24 → $3 | $0.2309 | n/a | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 | $1.00 | n/a | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $73 | $309.03 | n/a | 1 | Mar 12, 2020 |
Denali Therapeutics
May 22, 2026
Maintained: Buy
Price Target: $35 → $31
Current: $21.04
Upside: +47.34%
Spyre Therapeutics
May 12, 2026
Maintained: Buy
Price Target: $88 → $102
Current: $73.50
Upside: +38.78%
Praxis Precision Medicines
May 8, 2026
Maintained: Buy
Price Target: $437 → $420
Current: $349.97
Upside: +20.01%
Neurocrine Biosciences
May 7, 2026
Maintained: Hold
Price Target: $140 → $155
Current: $158.30
Upside: -2.08%
Axsome Therapeutics
May 5, 2026
Rated: Buy
Price Target: $281 → $280
Current: $234.48
Upside: +19.41%
Apogee Therapeutics
Apr 2, 2026
Reiterated: Buy
Price Target: $118
Current: $82.14
Upside: +43.66%
Sarepta Therapeutics
Mar 26, 2026
Maintained: Sell
Price Target: $12 → $14
Current: $17.87
Upside: -21.66%
AtaiBeckley
Mar 26, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $4.53
Upside: +164.90%
Xenon Pharmaceuticals
Mar 10, 2026
Maintained: Buy
Price Target: $60 → $90
Current: $54.73
Upside: +64.44%
Jazz Pharmaceuticals
Mar 5, 2026
Maintained: Buy
Price Target: $255 → $226
Current: $236.49
Upside: -4.44%
Feb 25, 2026
Maintained: Hold
Price Target: $36 → $30
Current: $31.59
Upside: -5.03%
Nov 13, 2025
Maintained: Buy
Price Target: $52 → $45
Current: $42.19
Upside: +6.66%
Sep 25, 2025
Maintained: Buy
Price Target: $35 → $29
Current: $21.66
Upside: +33.89%
Feb 11, 2025
Initiated Coverage: Buy
Price Target: $65
Current: $11.01
Upside: n/a
Jul 25, 2024
Initiated Coverage: Buy
Price Target: $7
Current: $2.60
Upside: n/a
Jul 17, 2024
Maintained: Buy
Price Target: $16
Current: $7.34
Upside: n/a
Mar 6, 2024
Maintained: Buy
Price Target: $16
Current: $3.87
Upside: n/a
Apr 26, 2023
Initiated Coverage: Hold
Price Target: $220
Current: $301.98
Upside: n/a
Apr 26, 2023
Initiated Coverage: Buy
Price Target: $80
Current: $77.91
Upside: n/a
Dec 7, 2022
Downgraded: Hold
Price Target: $24 → $3
Current: $0.2309
Upside: n/a
Sep 30, 2020
Maintained: Buy
Price Target: $19
Current: $1.00
Upside: n/a
Mar 12, 2020
Initiated Coverage: Buy
Price Target: $73
Current: $309.03
Upside: n/a